Back to Search
Start Over
LRRC15 inhibits SARS-CoV-2 cellular entry in trans.
- Source :
- PLoS Biology; 10/13/2022, Vol. 20 Issue 10, p1-29, 29p, 6 Graphs
- Publication Year :
- 2022
-
Abstract
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is mediated by the entry receptor angiotensin-converting enzyme 2 (ACE2). Although attachment factors and coreceptors facilitating entry are extensively studied, cellular entry factors inhibiting viral entry are largely unknown. Using a surfaceome CRISPR activation screen, we identified human LRRC15 as an inhibitory attachment factor for SARS-CoV-2 entry. LRRC15 directly binds to the receptor-binding domain (RBD) of spike protein with a moderate affinity and inhibits spike-mediated entry. Analysis of human lung single-cell RNA sequencing dataset reveals that expression of LRRC15 is primarily detected in fibroblasts and particularly enriched in pathological fibroblasts in COVID-19 patients. ACE2 and LRRC15 are not coexpressed in the same cell types in the lung. Strikingly, expression of LRRC15 in ACE2-negative cells blocks spike-mediated viral entry in ACE2+ cell in trans, suggesting a protective role of LRRC15 in a physiological context. Therefore, LRRC15 represents an inhibitory attachment factor for SARS-CoV-2 that regulates viral entry in trans. SARS-CoV-2 infection is mediated by the entry receptor ACE2, but cellular entry factors that inhibit viral entry are largely unknown. This study shows that human LRRC15 protein is expressed in pathological fibroblasts, directly binds to the receptor-binding domain of spike protein, and inhibits SARS-CoV-2 spike-mediated viral entry in neighboring cells. [ABSTRACT FROM AUTHOR]
- Subjects :
- SARS-CoV-2
COVID-19
Subjects
Details
- Language :
- English
- ISSN :
- 15449173
- Volume :
- 20
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- PLoS Biology
- Publication Type :
- Academic Journal
- Accession number :
- 159660497
- Full Text :
- https://doi.org/10.1371/journal.pbio.3001805